Insider Buying: Abeona Therapeutics (NASDAQ:ABEO) Director Buys 15,000 Shares of Stock

Abeona Therapeutics Inc. (NASDAQ:ABEO – Get Free Report) Director Faith Charles purchased 15,000 shares of Abeona Therapeutics stock in a transaction dated Friday, November 13th. The stock was acquired at an average price of $2.29 per share, for a total transaction of $34,350.00. Following the completion of the transaction, the director owned 191,407 shares in the company, valued at approximately $438,322.03. The trade was a 8.50% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Abeona Therapeutics Price Performance

Shares of NASDAQ:ABEO opened at $2.42 on Monday. Abeona Therapeutics Inc. has a fifty-two week low of $2.09 and a fifty-two week high of $7.65. The firm has a 50-day simple moving average of $4.70 and a 200 day simple moving average of $5.39. The company has a market cap of $138.30 million, a PE ratio of -2.26 and a beta of 1.50.

Abeona Therapeutics (NASDAQ:ABEO – Get Free Report) last issued its earnings results on Monday, November 9th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.09. Abeona Therapeutics had a negative net margin of 160.30% and a negative return on equity of 44.82%. The firm had revenue of $13.49 million for the quarter, compared to analysts’ expectations of $14.82 million. As a group, research analysts forecast that Abeona Therapeutics Inc. will post -0.97 EPS for the current fiscal year.

Analysts Set New Price Targets

ABEO has been the subject of several recent research reports. Oppenheimer reaffirmed an “outperform” rating and set a $21.00 target price (down from $22.00) on shares of Abeona Therapeutics in a report on Friday, August 14th. Roth Capital assumed coverage on Abeona Therapeutics in a report on Thursday, September 17th. They issued a “buy” rating and a $17.00 price target on the stock. Weiss Ratings lowered Abeona Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Tuesday, November 10th. Cantor Fitzgerald upped their price objective on Abeona Therapeutics from $28.00 to $30.00 and gave the stock an “overweight” rating in a research note on Friday, September 18th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Abeona Therapeutics in a research report on Friday, September 25th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Abeona Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $21.00.

Read Our Latest Analysis on ABEO

Institutional Trading of Abeona Therapeutics

Hedge funds have recently bought and sold shares of the company. Global Retirement Partners LLC grew its position in Abeona Therapeutics by 1,026.2% in the 3rd quarter. Global Retirement Partners LLC now owns 4,978 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 4,536 shares during the last quarter. Nan Fung Trinity HK Ltd. increased its stake in shares of Abeona Therapeutics by 336.6% in the third quarter. Nan Fung Trinity HK Ltd. now owns 552,270 shares of the biopharmaceutical company’s stock valued at $2,899,000 after purchasing an additional 425,770 shares during the period. AIGH Capital Management LLC bought a new stake in shares of Abeona Therapeutics during the third quarter valued at approximately $15,225,000. Simplify Asset Management Inc. bought a new stake in shares of Abeona Therapeutics during the third quarter valued at approximately $1,451,000. Finally, WINTON GROUP Ltd bought a new stake in shares of Abeona Therapeutics during the second quarter valued at approximately $256,000. 80.56% of the stock is currently owned by institutional investors.

Abeona Therapeutics Company Profile

(Get Free Report)

Abeona Therapeutics, Inc. is a biotechnology company focused on developing cell and gene therapies for serious and rare diseases. Its work includes treatments designed to address the underlying genetic causes of disease. The company’s lead product, ZEVASKYN (prademagene zamikeracel), is an autologous gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa, a rare inherited skin disorder. Made from a patient’s skin cells, the therapy uses genetic modification to help cells produce type VII collagen and is applied to wounds.

See Also

Insider Buying and Selling by Quarter for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.